Alphagan-P Shows Promise in Correcting Post-LASIK Low Residual Myopia : Study
Advertisement
A new study published in PLOS ONE suggests that Alphagan-P (brimonidine tartrate ophthalmic solution 0.15%) could be an effective option for managing low residual myopia after LASIK surgery. The research found that around 50% of patients experienced a reduction of up to 0.5 diopters in residual myopia following treatment with Alphagan-P.
Residual myopia—commonly reported after LASIK—can affect patient satisfaction and visual clarity. While enhancements or retreatment are possible, not all patients are eligible or willing to undergo further laser correction. That’s where topical therapies like Alphagan-P may offer a non-invasive, pharmacological alternative. The researchers conducted a prospective analysis of post-LASIK patients with low levels of residual myopia who were administered Alphagan-P twice daily. Over the treatment period, a statistically significant improvement in refractive error was observed in approximately half the cohort. The proposed mechanism behind the drug’s effect is its ability to induce miosis (pupil constriction), which can improve depth of focus and reduce refractive error, particularly in dim light or near tasks. The therapy was generally well tolerated, with only minor side effects reported.
Reference:
Haider, A., Rizwan, M. S., Nadeem, M., Javed, M. R., & Jameel, A. (2024). Use of topical brimonidine tartrate (Alphagan-P) for residual myopia after LASIK. PLOS ONE, 19(7), e0329364. https://doi.org/10.1371/journal.pone.0329364
Keywords: Alphagan-P, residual myopia, LASIK, brimonidine tartrate, non-surgical vision correction, diopter reduction, post-LASIK outcomes, pharmacological refractive correction
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.